



Date: 11th December, 2025

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex Bandra (East) Mumbai - 400 051 <i>Stock Code : INDOCO</i>	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, Mumbai - 400 001 <i>Stock Code : 532612</i>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is further to the intimation given by the Company dated 19th September, 2025, regarding successful completion of United States Food and Drug Administration (USFDA) inspection at Company's Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga.

Further to the aforesaid information, we are now pleased to enclose a Press Release regarding the receipt of the Establishment Inspection Report from the USFDA for the Company's API manufacturing facility located at Patalganga.

The same is for your information and records.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**



**Ramanathan Hariharan
Company Secretary & Head Legal**



PRESS RELEASE

Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga

December 11, 2025, Mumbai: Indoco Remedies Limited (Indoco) announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following a successful inspection of the said facility from 15th September, 2025 to 19th September, 2025.

Ms. Aditi Panandikar, Managing Director, Indoco said, "We are pleased to have received the EIR from the USFDA for our API manufacturing facility located at Patalganga. This further reinforces our commitment to upholding the highest standards of quality and compliance, delivering trusted healthcare solutions to patients worldwide."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexitin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media enquiries please contact:

Corporate Communications | +91 22 62871000

E-mail: corpcom@indoco.com